By Nick Stride
|
Friday 16th November 2001 |
Text too small? |
GARY PAYKEL: Rejected criticism
|
F&P Healthcare American Depositary Shares finished Wednesday's Nasdaq market trading at $US26.05, a gain of 44.7% on the $US18 at which they were sold to US and other institutions on Tuesday.
F&P chief executive Gary Paykel earlier this month rejected criticism from institutional shareholders and sharebroking analysts that the $US16-18 an ADS "indicative price" it had set for the sale of 17.6 million Healthcare shares was far too low.
At $US26.05 the shares sold had gained $35 million ($83.5 million) in value in two days.
Arcus Investment Management's Simon Botherway said the sale, as predicted, had resulted in "a massive value transfer from Australasian investors to North American investors. I can assure you I'm not the only person who's extremely unhappy with this."
Fund managers Alliance Capital, BT Funds Management and New Zealand Funds Management and sharebroker Credit Suisse First Boston had also warned the float was too cheaply priced.
Healthcare shares were trading on the local market today at $15.70, up from the $10.95 at which the float price valued them.
No comments yet
SKT - Sky ASM - Q1 Dividend Announced and Guidance Reiterated
TRA - Turners absorbs oil shock to deliver a record first half
Devon Funds Morning Note - 20 November 2026
IFT - Lodgement of Product Disclosure Statement for Capital Bond
LOD - Lodestone Energy delivers strong growth
FSF - Fonterra increases FY27 forecast Farmgate Milk Price
November 20th Morning Report
RGI - Reefton Resource Update and PFS
Devon Funds Morning Note - 19 November 2026
RYM - Ryman appoints two new directors